- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00404820
Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis (ROSE)
June 6, 2011 updated by: Novartis
A Multi-center, Randomized, Open-label, Controlled, One-year Trial to Measure the Effect of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteopenia and Osteoporosis
The aim of this study was to examine the effect of zoledronic acid and alendronate on bone metabolism as measured by biomarkers in postmenopausal women with osteoporosis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
604
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Multiple Cities, Germany
- For site information contact Novartis Pharmaceuticals
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
55 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Low bone mineral density (as indicated by a "t-score" of -2.0 or lower) postmenopausal women
Exclusion Criteria:
- Previous use of oral and iv bisphosphonates, parathormone, strontium ranelate, sodium fluoride.
Other protocol-defined inclusion/exclusion criteria applied to the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Zoledronic acid 5 mg
Patients received zoledronic acid 5 mg in 100 ml solution in a 15 minute intravenous (iv) infusion once per year.
The peripheral iv infusion was preceded by and followed by a 10 ml normal saline flush of the intravenous line.
In addition to study therapy, all participants received 1200 mg elemental calcium and 800 IU of vitamin D daily.
Calcium and vitamin D were supplied in a chewable tablet that was to be taken twice daily.
|
Zoledronic acid was supplied as a concentrate of 5.33 mg zoledronic acid monohydrate in a 100 ml solution.
5.33 mg zoledronic acid monohydrate equals 5 mg zoledronic acid.
Combined elemental calcium / vitamin D chewable tablets.
Participants took 2 tablets a day, for a daily dose of calcium 1200 mg/vitamin D 800 IU.
|
Active Comparator: Alendronate 70 mg
Patients received an alendronate 70 mg tablet once weekly with 200 ml of tap water in the morning on an empty stomach at least 30 minutes before the first meal.
Patients were to remain in an upright position for 30 minutes after swallowing the tablet.
In addition to study therapy, all participants received 1200 mg elemental calcium and 800 IU of vitamin D daily.
Calcium and vitamin D were supplied in a chewable tablet that was to be taken twice daily.
|
Combined elemental calcium / vitamin D chewable tablets.
Participants took 2 tablets a day, for a daily dose of calcium 1200 mg/vitamin D 800 IU.
Patients received an alendronate 70 mg tablet once weekly with 200 ml of tap water in the morning on an empty stomach at least 30 minutes before the first meal.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of Cross-linked N-telopeptide of Type I Collagen (NTx) Level Assessed as Standardized Area Under the Curve From Screening to Month 12 in the Intent-to-Treat Population
Time Frame: Screening to end of study (Month 12)
|
The level of bone activity as measured by NTx over the course of 12 months was assessed using the standardized area under the curve.
Blood samples were collected after an overnight fast of at least 8 hours between 7:00 and 11:00 AM at Screening and Months 1.5, 3, 6, 9, and 12 months after baseline.
Serum was analyzed at a central lab using commercially available ELISA kits.
Standardized AUC was calculated by the AUC divided by the number of days the patient participated in the study.
|
Screening to end of study (Month 12)
|
Change of Cross-linked N-telopeptide of Type I Collagen (NTx) Level Assessed as Standardized Area Under the Curve From Screening to Month 12 in the Per Protocol Population
Time Frame: Screening to end of study (Month 12)
|
The level of bone activity as measured by NTx over the course of 12 months was assessed using the standardized area under the curve.
Blood samples were collected after an overnight fast of at least 8 hours between 7:00 and 11:00 AM at Screening and Months 1.5, 3, 6, 9, and 12 months after baseline.
Serum was analyzed at a central lab using commercially available ELISA kits.
Standardized AUC was calculated by the AUC divided by the number of days the patient participated in the study.
|
Screening to end of study (Month 12)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of Procollagen Type I Nitrogenous Propeptide (P1NP) Level Assessed as Standardized Area Under the Curve From Screening to Month 12
Time Frame: Screening to end of study (Month 12)
|
The level of bone activity as measured by P1NP over the course of 12 months was assessed using the standardized area under the curve.
Blood samples were collected after an overnight fast of at least 8 hours between 7:00 and 11:00 AM at Screening and Months 1.5, 3, 6, 9, and 12 months after baseline.
Serum was analyzed at a central lab using commercially available ELISA kits.
Standardized AUC was calculated by the AUC divided by the number of days the patient participated in the study.
|
Screening to end of study (Month 12)
|
Change in the Qualeffo-41 Quality of Life (QoL) Questionnaire Score From Baseline to Month 12
Time Frame: Baseline to end of study (Month 12)
|
The Qualeffo-41 QoL questionnaire was completed by the patient at Baseline and at Month 12.
The questionnaire includes 41 questions covering 7 domains (pain, physical function and activities of daily living, physical function and jobs around the house, physical function and mobility, leisure and social activities, general health perception, mental function).
Scores on each question range from 1 to 3, 4, or 5.
The total score summed over all questions ranges from 41-205 points; the lower the score the higher the quality of life.
A negative change score indicates improvement.
|
Baseline to end of study (Month 12)
|
Number of Patients With a Clinical Fracture From Baseline to Month 12
Time Frame: Baseline to end of study (Month 12)
|
A diagnosis of clinical fracture was based on physical examination findings, ie, swelling, tenderness, limited movement, pain.
|
Baseline to end of study (Month 12)
|
Change in Body Height From Baseline to Month 12
Time Frame: Baseline to end of study (Month 12)
|
Body height was measured at Baseline and at the end of the study (Month 12) and the change in height calculated.
|
Baseline to end of study (Month 12)
|
Therapy Preference at End of Study (Month 12)
Time Frame: Month 12
|
Patients were administered a questionnaire at the end of the study in which they were asked which type of therapy, weekly oral or yearly iv, they preferred.
|
Month 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Novartis Pharma GmbH, Germany +49 911 273-0, Novartis
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2006
Primary Completion (Actual)
December 1, 2008
Study Completion (Actual)
December 1, 2008
Study Registration Dates
First Submitted
November 28, 2006
First Submitted That Met QC Criteria
November 28, 2006
First Posted (Estimate)
November 29, 2006
Study Record Updates
Last Update Posted (Estimate)
July 1, 2011
Last Update Submitted That Met QC Criteria
June 6, 2011
Last Verified
June 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CZOL446HDE31
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoporosis
-
Radius Health, Inc.CompletedOsteoporosis | Osteoporosis Risk | Osteoporosis, Postmenopausal | Osteoporosis Fracture | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of Vertebrae | Osteoporosis VertebralUnited States
-
Radius Health, Inc.CompletedOsteoporosis | Age Related Osteoporosis | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of VertebraeUnited States, Poland, Italy
-
Hoffmann-La RocheCompletedPostmenopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States, Puerto Rico
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, FranceRecruitingPost Menopausal OsteoporosisFrance
-
AmgenCompletedPost Menopausal OsteoporosisFrance
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisSpain, South Africa, Germany, Mexico, United States, Canada, France, United Kingdom, Italy, Belgium, Australia, Poland, Denmark, Hungary, Czech Republic, Norway
-
Hoffmann-La RocheGlaxoSmithKlineCompletedPost Menopausal OsteoporosisFrance
-
Novartis PharmaceuticalsCompletedPost-menopausal OsteoporosisColombia, Belgium, Sweden, Hong Kong, United States, Hungary, Switzerland, Australia, Germany, Italy, Canada, Poland, Argentina, Thailand, Norway, New Zealand, France, Finland
Clinical Trials on Zoledronic acid 5 mg solution
-
Oslo University HospitalCompletedNeovascular Age-related Macular DegenerationNorway
-
Novartis PharmaceuticalsCompletedMale OsteoporosisRussian Federation, Argentina, Switzerland, United Kingdom, Germany, Belgium, Czechia, Finland, Spain, Brazil, Romania, Hungary, Denmark, Poland, Norway, Sweden, Austria, South Africa, Slovakia, Australia, Iceland, Italy, Portugal
-
University of NebraskaCompletedBone Loss | Bariatric Surgery Candidate | Bone ResorptionUnited States
-
Assiut UniversityRecruitingUse of Zoledronic Acid in Breast CancerEgypt
-
Novartis PharmaceuticalsCompletedNon-Small-Cell Lung CancerGreece, Taiwan, Germany, Belgium, Italy, Spain, United Kingdom, Korea, Republic of, Netherlands, China, Hungary, Poland, France, Thailand, Portugal
-
University of Colorado, DenverRecruitingCarcinoma, Non-Small-Cell LungUnited States
-
Ludwig-Maximilians - University of MunichEli Lilly and Company; Sanofi; Novartis; AstraZeneca; Chugai Pharma USA; Janssen Diagnostics...Completed
-
University of CalgaryRecruitingOsteo Arthritis Knee | Anterior Cruciate Ligament Injuries | Anterior Cruciate Ligament Rupture | Anterior Cruciate Ligament TearCanada
-
Yonsei UniversityRecruiting
-
Novartis PharmaceuticalsCompleted